{"id":"enarodustat","rwe":[{"pmid":"41818346","year":"2026","title":"The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (recombinant human erythropoietin), Open-Label Study：the ENARODIAL study.","finding":"","journal":"American journal of nephrology","studyType":"Clinical Study"},{"pmid":"41635559","year":"2026","title":"A Phase 3 Study of Enarodustat in Chinese Patients Undergoing Peritoneal Dialysis for Treatment of Anemia: The ENAROPERA Study.","finding":"","journal":"Kidney diseases (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41576104","year":"2026","title":"Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"41319981","year":"2026","title":"Prolyl-hydroxylase domain inhibition enhances collagen levels in oral mucosa-derived fibroblasts.","finding":"","journal":"Biochimica et biophysica acta. Molecular basis of disease","studyType":"Clinical Study"},{"pmid":"41276953","year":"2026","title":"Characterization of Novel Enarodustat Metabolites Using Liquid Chromatography-High Resolution Mass Spectrometry for Doping Control Purposes.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Egl nine homolog 1","category":"target"},{"label":"EGLN1","category":"gene"},{"label":"EGLN2","category":"gene"},{"label":"EGLN3","category":"gene"},{"label":"Active","category":"status"},{"label":"Anemia in chronic kidney disease","category":"indication"},{"label":"Anemia of renal disease","category":"indication"},{"label":"Japan Tabacco","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Japan Tabacco","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ENARODUSTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:06:39.065203+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:06:55.841746+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:06:46.018090+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ENARODUSTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:06:47.362870+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Egl nine homolog 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:06:47.929969+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297619/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:06:47.822850+00:00"}},"allNames":"enaroy","offLabel":[],"synonyms":["enarodustat","enaroy","JTZ-951"],"timeline":[{"date":"2020-09-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Japan Tabacco)"}],"aiSummary":"Enarodustat (Enaroy), developed by Japan Tobacco, is a marketed drug for anemia in chronic kidney disease, positioning it in a niche but critical therapeutic area. Its key strength lies in its unique mechanism of action, inhibiting Egl nine homolog 1 to regulate erythropoietin production, distinguishing it from other treatments. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"2020-09-25","orphan":false,"company":"Japan Tabacco","regulator":"PMDA"}],"brandName":"Enaroy","ecosystem":[{"indication":"Anemia in chronic kidney disease","otherDrugs":[{"name":"daprodustat","slug":"daprodustat","company":"Glaxosmithkline"},{"name":"epoetin alfa","slug":"epoetin-alfa","company":"Amgen"},{"name":"methoxy polyethylene glycol-epoetin beta","slug":"methoxy-polyethylene-glycol-epoetin-beta","company":"Hoffman-La Roche"},{"name":"nandrolone decanoate","slug":"nandrolone-decanoate","company":"Aspen Global Inc"}],"globalPrevalence":850000000},{"indication":"Anemia of renal disease","otherDrugs":[{"name":"daprodustat","slug":"daprodustat","company":"Glaxosmithkline"},{"name":"darbepoetin alfa","slug":"darbepoetin-alfa","company":"Amgen"}],"globalPrevalence":null}],"mechanism":{"target":"Egl nine homolog 1","targets":[{"gene":"EGLN1","source":"DrugCentral","target":"Egl nine homolog 1","protein":"Egl nine homolog 1"},{"gene":"EGLN2","source":"DrugCentral","target":"Egl nine homolog 2","protein":"Egl nine homolog 2"},{"gene":"EGLN3","source":"DrugCentral","target":"Egl nine homolog 3","protein":"Egl nine homolog 3"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Enaroy specifically inhibits the activity of Egl nine homolog 1, leading to increased erythropoietin production and subsequent erythropoiesis, which helps to alleviate anemia in patients with chronic kidney disease and anemia of renal disease."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5427","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ENARODUSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ENARODUSTAT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:55:47.565954","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:06:55.841890+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"daprodustat","drugSlug":"daprodustat","fdaApproval":"2023-02-01","patentExpiry":"Mar 13, 2038","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"enarodustat","indications":{"approved":[{"name":"Anemia in chronic kidney disease","source":"DrugCentral","snomedId":707323002,"regulator":"FDA","usPrevalence":37000000,"globalPrevalence":850000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"},{"name":"Anemia of renal disease","source":"DrugCentral","snomedId":234348004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daprodustat","brandName":"daprodustat","genericName":"daprodustat","approvalYear":"2023","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06725810","phase":"PHASE4","title":"Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-27","conditions":["Chronic Kidney Disease Associated Anemia"],"enrollment":1670,"completionDate":"2029-02-01"},{"nctId":"NCT07079579","phase":"PHASE4","title":"Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2025-08","conditions":["Renal Anemia in Non-dialysis Chronic Kidney Disease"],"enrollment":120,"completionDate":"2027-12"},{"nctId":"NCT06737081","phase":"PHASE2","title":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2024-09-14","conditions":["Anemia"],"enrollment":60,"completionDate":"2026-06-30"},{"nctId":"NCT06720025","phase":"PHASE3","title":"Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2023-09-19","conditions":["Anemia"],"enrollment":100,"completionDate":"2024-06-20"},{"nctId":"NCT06720233","phase":"PHASE3","title":"Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2002-02-22","conditions":["Anemia"],"enrollment":37,"completionDate":"2024-10-28"},{"nctId":"NCT04027517","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-01-15","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":172,"completionDate":"2021-02-23"},{"nctId":"NCT02805244","phase":"PHASE1","title":"Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2016-06","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":6,"completionDate":"2016-09"},{"nctId":"NCT02581124","phase":"PHASE1","title":"Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2015-10","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":10,"completionDate":"2016-04"},{"nctId":"NCT01971164","phase":"PHASE1","title":"Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2013-05","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":29,"completionDate":"2014-07"},{"nctId":"NCT01978587","phase":"PHASE1","title":"Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2013-10","conditions":["Anemia in Chronic Kidney Disease"],"enrollment":6,"completionDate":"2014-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"JSK7TUA223","INN_ID":"10572","UMLSCUI":"C5139933","chemblId":"CHEMBL4297619","ChEMBL_ID":"CHEMBL4297619","KEGG_DRUG":"D11523","DRUGBANK_ID":"DB14985","PUBCHEM_CID":"50899324","IUPHAR_LIGAND_ID":"11828","MESH_SUPPLEMENTAL_RECORD_UI":"C000656654"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Japan Tabacco","relationship":"Current Owner"}],"publicationCount":55,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 12","pmid":"41818346","title":"The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (recombinant human erythropoietin), Open-Label Study：the ENARODIAL study.","journal":"American journal of nephrology"},{"date":"2026 Jan-Dec","pmid":"41635559","title":"A Phase 3 Study of Enarodustat in Chinese Patients Undergoing Peritoneal Dialysis for Treatment of Anemia: The ENAROPERA Study.","journal":"Kidney diseases (Basel, Switzerland)"},{"date":"2026","pmid":"41576104","title":"Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation.","journal":"PloS one"},{"date":"2026 Mar","pmid":"41319981","title":"Prolyl-hydroxylase domain inhibition enhances collagen levels in oral mucosa-derived fibroblasts.","journal":"Biochimica et biophysica acta. Molecular basis of disease"},{"date":"2026 Feb","pmid":"41276953","title":"Characterization of Novel Enarodustat Metabolites Using Liquid Chromatography-High Resolution Mass Spectrometry for Doping Control Purposes.","journal":"Drug testing and analysis"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Japan Tabacco","companyId":"japan-tabacco","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-09-25T00:00:00.000Z","mah":"Japan Tabacco","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:06:55.841890+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}